Zometa and Posterior reversible encephalopathy syndrome - a phase IV clinical study of FDA data

Summary:

Posterior reversible encephalopathy syndrome is reported as a side effect among people who take Zometa (zoledronic acid), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Cabozantinib, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Posterior reversible encephalopathy syndrome when taking Zometa. It is created by eHealthMe based on reports of 71,074 people who have side effects when taking Zometa from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Posterior reversible encephalopathy syndrome?

Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss) is found to be associated with 470 drugs and 1,007 conditions by eHealthMe. Check the latest studies of Posterior reversible encephalopathy syndrome.

On Jul, 08, 2026

71,074 people reported to have side effects when taking Zometa.
Among them, 12 people (0.02%) have Posterior reversible encephalopathy syndrome.

Could Zometa cause Posterior reversible encephalopathy syndrome?

Among these 12 people:

How long have people been on Zometa when they have Posterior reversible encephalopathy syndrome? *

What is the gender of people who have Posterior reversible encephalopathy syndrome when taking Zometa? *

female: 80 %
male: 20 %

What is the age of people who have Posterior reversible encephalopathy syndrome when taking Zometa? *

What are other drugs people take besides Zometa? *

Zopiclone: 4 people, 33.33%
Cabozantinib: 4 people, 33.33%
Movicol: 3 people, 25.00%
Paracetamol: 2 people, 16.67%
Xgeva: 2 people, 16.67%
Novalgin: 2 people, 16.67%
Aredia: 2 people, 16.67%
Glucophage: 2 people, 16.67%
Hydrocodone Bitartrate And Acetaminophen: 1 person, 8.33%
Fluoxetine: 1 person, 8.33%

What are other side effects people have besides Posterior reversible encephalopathy syndrome? *

Back Pain: 4 people, 33.33%
Pain: 4 people, 33.33%
Diarrhea: 3 people, 25.00%
Bone Fissure: 3 people, 25.00%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 3 people, 25.00%
Rashes (redness): 3 people, 25.00%
Pneumonia: 3 people, 25.00%
Fever: 3 people, 25.00%
Cough: 3 people, 25.00%
Pain In Extremity: 3 people, 25.00%

What are the existing conditions these people have? *

Hypercalcaemia (elevated calcium (ca+) level in the blood): 6 people, 50.00%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 33.33%
Stress And Anxiety: 4 people, 33.33%
Nausea (feeling of having an urge to vomit): 3 people, 25.00%
Osteoporosis (bones weak and more likely to break): 2 people, 16.67%
Metastases To Bone (cancer spreads to bone): 2 people, 16.67%
Pain: 2 people, 16.67%
Feeling Hot: 2 people, 16.67%
Dyspnea (difficult or laboured breathing): 2 people, 16.67%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and have Posterior reversible encephalopathy syndrome?

- Check whether Posterior reversible encephalopathy syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zometa:

Zometa (71,434 reports)

Posterior reversible encephalopathy syndrome treatments and more:

Posterior reversible encephalopathy syndrome (9,125 reports)

How severe was Posterior reversible encephalopathy syndrome and when was it recovered:

Posterior reversible encephalopathy syndrome in Zometa

Expand to all the drugs that have ingredients of zoledronic acid:

Posterior reversible encephalopathy syndrome and drugs with ingredients of zoledronic acid (21 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zometa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Posterior reversible encephalopathy syndrome:

Posterior reversible encephalopathy syndrome (470 drugs)

Browse all the conditions that are associated with Posterior reversible encephalopathy syndrome:

Posterior reversible encephalopathy syndrome (1,007 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zometa) and Zometa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.